Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | August 20, 2026 | August 21, 2026 |
| Provention Bio, Inc.PRVB · Entity 12101 | Director | May 17, 2022 | May 18, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date August 20, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,066 |
Ending reported balance
After 2026-08-20 transaction · row 10
10 source rows · reconciled sequenceRow 1 · 2026-08-20 · Exercise / conversion · Acquired 1,165 · Balance 11,231 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Row 2 · 2026-08-20 · Sale · Disposed 1,165 · Balance 10,066 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. F2: Sale prices for the transactions reported range from $143.31 to $144.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Row 3 · 2026-08-20 · Exercise / conversion · Acquired 1,816 · Balance 11,882 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Row 4 · 2026-08-20 · Sale · Disposed 1,816 · Balance 10,066 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. F3: Sale prices for the transactions reported range from $144.32 to $145.31. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Row 5 · 2026-08-20 · Exercise / conversion · Acquired 1,658 · Balance 11,724 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Row 6 · 2026-08-20 · Sale · Disposed 1,658 · Balance 10,066 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. F4: Sale prices for the transactions reported range from $145.34 to $146.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Row 7 · 2026-08-20 · Exercise / conversion · Acquired 26 · Balance 10,092 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Row 8 · 2026-08-20 · Sale · Disposed 26 · Balance 10,066 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Row 9 · 2026-08-20 · Exercise / conversion · Acquired 335 · Balance 10,401 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Row 10 · 2026-08-20 · Sale · Disposed 335 · Balance 10,066 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.45 · Expires 2031-05-12 | Direct | 0 |
Reported balance
After 2026-08-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-08-20 · Exercise / conversion · Disposed 4,665 · Balance 0 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. F5: 25% of the shares subject to the option vested on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option are fully vested. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.35 · Expires 2032-05-05 | Direct | 11,395 |
Reported balance
After 2026-08-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-08-20 · Exercise / conversion · Disposed 335 · Balance 11,395 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. F6: 100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.
F2: Sale prices for the transactions reported range from $143.31 to $144.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F3: Sale prices for the transactions reported range from $144.32 to $145.31. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F4: Sale prices for the transactions reported range from $145.34 to $146.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F5: 25% of the shares subject to the option vested on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option are fully vested.
F6: 100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022.
Provention Bio, Inc.
Report date May 17, 2022 · Filed May 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.52 · Expires 2032-05-17 | Direct | 33,000 |
Reported balance
After 2022-05-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-17 · Grant · Acquired 33,000 · Balance 33,000 F2: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1: The options will vest in full and become exercisable upon the earlier to occur of (a) the business day before the Issuer's next annual meeting of stockholders and (b) May 17, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest in full and become exercisable upon the earlier to occur of (a) the business day before the Issuer's next annual meeting of stockholders and (b) May 17, 2023.
F2: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 335 | $0.00 Strike: $61.35 | $0.00 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · derivative · entry 12 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,395 Underlying: Common Stock · 335 shares Expires 2032-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. F6 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 4,665 | $0.00 Strike: $67.45 | $0.00 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · derivative · entry 11 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,665 shares Expires 2031-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. F5 · derivative.exercise_date: 25% of the shares subject to the option vested on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option are fully vested. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 335 | $146.26 | $48,997.10 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · nonDerivative · entry 10 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,066 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 335 | $61.35 | $20,552.25 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · nonDerivative · entry 9 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 26 | $146.36 | $3,805.36 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · nonDerivative · entry 8 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,066 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 26 | $67.45 | $1,753.70 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · nonDerivative · entry 7 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,658 | $145.73 | $241,618.02 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · nonDerivative · entry 6 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,066 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. F4 · price: Sale prices for the transactions reported range from $145.34 to $146.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,658 | $67.45 | $111,832.10 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · nonDerivative · entry 5 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,816 | $144.92 | $263,183.44 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · nonDerivative · entry 4 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,066 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. F3 · price: Sale prices for the transactions reported range from $144.32 to $145.31. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,816 | $67.45 | $122,489.20 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · nonDerivative · entry 3 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,165 | $143.75 | $167,473.76 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · nonDerivative · entry 2 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,066 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. F2 · price: Sale prices for the transactions reported range from $143.31 to $144.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,165 | $67.45 | $78,579.25 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · nonDerivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Read SEC document |
| April 30, 2026 Filed May 4, 2026 20:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 4,884 | $0.00 Strike: $130.84 | $0.00 |
DisclosureSEC source: 0000882095-26-000010 · wk-form4_1777927225.xml · derivative · entry 2 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,884 Underlying: Common Stock · 4,884 shares Expires 2036-04-30 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026. Read SEC document |
| April 30, 2026 Filed May 4, 2026 20:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 1,146 | $0.00 | $0.00 |
DisclosureSEC source: 0000882095-26-000010 · wk-form4_1777927225.xml · nonDerivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,066 F1 · security: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026. Read SEC document |
| January 20, 2026 Filed Jan 21, 2026 21:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $67.45 | $0.00 |
DisclosureSEC source: 0001771814-26-000002 · wk-form4_1769030768.xml · derivative · entry 3 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,665 Underlying: Common Stock · 5,000 shares Expires 2031-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025. F2 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| January 20, 2026 Filed Jan 21, 2026 21:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $123.50 | $617,500.00 |
DisclosureSEC source: 0001771814-26-000002 · wk-form4_1769030768.xml · nonDerivative · entry 2 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,920 F1 · kind: The transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025. Read SEC document |
| January 20, 2026 Filed Jan 21, 2026 21:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $67.45 | $337,250.00 |
DisclosureSEC source: 0001771814-26-000002 · wk-form4_1769030768.xml · nonDerivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025. Read SEC document |
| November 28, 2025 Filed Dec 1, 2025 23:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $64.92 | $0.00 |
DisclosureSEC source: 0001771814-25-000005 · wk-form4_1764630716.xml · derivative · entry 3 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,648 Underlying: Common Stock · 5,000 shares Expires 2034-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 8, 2024. Read SEC document |
| November 28, 2025 Filed Dec 1, 2025 23:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $125.08 | $625,400.00 |
DisclosureSEC source: 0001771814-25-000005 · wk-form4_1764630716.xml · nonDerivative · entry 2 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,920 Read SEC document |
| November 28, 2025 Filed Dec 1, 2025 23:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $64.92 | $324,600.00 |
DisclosureSEC source: 0001771814-25-000005 · wk-form4_1764630716.xml · nonDerivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 14, 2025 Filed Jul 15, 2025 19:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $67.45 | $0.00 |
DisclosureSEC source: 0001127602-25-019182 · form4.xml · derivative · entry 3 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,665 Underlying: Common Stock · 5,000 shares Expires 2031-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025. F2 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| July 14, 2025 Filed Jul 15, 2025 19:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $109.74 | $548,700.00 |
DisclosureSEC source: 0001127602-25-019182 · form4.xml · nonDerivative · entry 2 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,920 F1 · kind: The transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025. Read SEC document |
| July 14, 2025 Filed Jul 15, 2025 19:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $67.45 | $337,250.00 |
DisclosureSEC source: 0001127602-25-019182 · form4.xml · nonDerivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025. Read SEC document |
| May 07, 2025 Filed May 9, 2025 00:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 6,809 | $0.00 Strike: $98.90 | $0.00 |
DisclosureSEC source: 0001127602-25-013771 · form4.xml · derivative · entry 2 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,809 Underlying: Common Stock · 6,809 shares Expires 2035-05-07 F3 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 7, 2025. Read SEC document |
| May 07, 2025 Filed May 9, 2025 00:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 1,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013771 · form4.xml · derivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,713 Underlying: Common Stock · 1,516 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested immediately upon the grant date of May 7, 2025. F2 · derivative.expiration_date: 100% of the restricted stock units vested immediately upon the grant date of May 7, 2025. Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 23:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 4,121 | $0.00 Strike: $61.35 | $0.00 |
DisclosureSEC source: 0001127602-24-028213 · form4.xml · derivative · entry 5 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,730 Underlying: Common Stock · 4,121 shares Expires 2032-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022. Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 23:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 5,879 | $0.00 Strike: $61.17 | $0.00 |
DisclosureSEC source: 0001127602-24-028213 · form4.xml · derivative · entry 4 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,879 shares Expires 2030-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary measured from December 8, 2020 such that 100% of the shares subject to the option will be fully vested and exercisable on December 8, 2021. Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 23:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 6,788 | $91.39 | $620,356.00 |
DisclosureSEC source: 0001127602-24-028213 · form4.xml · nonDerivative · entry 3 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,920 F1 · price: Sale prices reported for the transactions reported here range from $91.3901 to $91.3910. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 23:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 4,121 | $61.35 | $252,823.35 |
DisclosureSEC source: 0001127602-24-028213 · form4.xml · nonDerivative · entry 2 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 23:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,879 | $61.17 | $359,618.43 |
DisclosureSEC source: 0001127602-24-028213 · form4.xml · nonDerivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2024 Filed May 9, 2024 21:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 12,648 | $0.00 Strike: $64.92 | $0.00 |
DisclosureSEC source: 0001127602-24-014809 · form4.xml · derivative · entry 2 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,648 Underlying: Common Stock · 12,648 shares Expires 2034-05-08 F3 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 8, 2024. Read SEC document |
| May 08, 2024 Filed May 9, 2024 21:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 2,310 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-014809 · form4.xml · derivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,197 Underlying: Common Stock · 2,310 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested immediately upon the grant date of May 8, 2024. F2 · derivative.expiration_date: 100% of the restricted stock units vested immediately upon the grant date of May 8, 2024. Read SEC document |
| May 03, 2023 Filed May 4, 2023 22:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 10,173 | $79.45 Strike: $79.45 | $808,244.85 |
DisclosureSEC source: 0001127602-23-014562 · form4.xml · derivative · entry 2 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,173 Underlying: Common Stock · 10,173 shares Expires 2033-05-03 F3 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 3, 2023. Read SEC document |
| May 03, 2023 Filed May 4, 2023 22:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 1,887 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-014562 · form4.xml · derivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,887 Underlying: Common Stock · 1,887 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested immediately upon the grant date of May 3, 2023. F2 · derivative.expiration_date: 100% of the restricted stock units vested immediately upon the grant date of May 3, 2023. Read SEC document |
| May 17, 2022 Filed May 18, 2022 18:02 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantStock Option (right to buy) · Derivative | 33,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001493152-22-014361 · ownership.xml · derivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock, par value $0.0001 · 33,000 shares Expires 2032-05-17 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: The options will vest in full and become exercisable upon the earlier to occur of (a) the business day before the Issuer's next annual meeting of stockholders and (b) May 17, 2023. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 15,851 | $0.00 Strike: $61.35 | $0.00 |
DisclosureSEC source: 0001127602-22-013726 · form4.xml · derivative · entry 2 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,851 Underlying: Common Stock · 15,851 shares Expires 2032-05-05 F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 2,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013726 · form4.xml · nonDerivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,708 F1 · security: Represents 2,444 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 5, 2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013129 · form4.xml · derivative · entry 2 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,223 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 3, 2022. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 3, 2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013129 · form4.xml · nonDerivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| December 08, 2021 Filed Dec 9, 2021 18:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,041 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-030577 · form4.xml · derivative · entry 2 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,223 Underlying: Common Stock · 1,041 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on December 8, 2021. F2 · derivative.expiration_date: 100% of the restricted stock units vested on December 8, 2021. Read SEC document |
| December 08, 2021 Filed Dec 9, 2021 18:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,041 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-030577 · form4.xml · nonDerivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 12, 2021 Filed May 14, 2021 19:47 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantStock Option (right to buy) · Derivative | 23,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001493152-21-011586 · ownership.xml · derivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock, par value $0.0001 · 23,000 shares Expires 2031-05-12 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: The options will vest in full and become exercisable upon the earlier to occur of (a) the business day before the Issuer's next annual meeting of stockholders and (b) May 12, 2022. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 14,665 | $0.00 Strike: $67.45 | $0.00 |
DisclosureSEC source: 0001127602-21-016844 · form4.xml · derivative · entry 2 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,665 Underlying: Common Stock · 14,665 shares Expires 2031-05-12 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-016844 · form4.xml · derivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,264 Underlying: Common Stock · 2,223 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 21:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 1,041 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-031071 · form4.xml · derivative · entry 2 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,041 Underlying: Common Stock · 1,041 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units vest on December 8, 2021. F3 · derivative.expiration_date: 100% of the restricted stock units vest on December 8, 2021. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 21:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 5,879 | $0.00 Strike: $61.17 | $0.00 |
DisclosureSEC source: 0001127602-20-031071 · form4.xml · derivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,879 Underlying: Common Stock · 5,879 shares Expires 2030-12-08 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary measured from December 8, 2020 such that 100% of the shares subject to the option will be fully vested and exercisable on December 8, 2021. Read SEC document |
| July 15, 2020 Filed Jul 16, 2020 18:01 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantOption (right to buy) · Derivative | 22,200 | $0.00 Strike: $12.62 | $0.00 |
DisclosureSEC source: 0001493152-20-013472 · ownership.xml · derivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,200 Underlying: Common Stock, par value $0.0001 · 22,200 shares Expires 2030-07-15 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: 22,200 option shares vest on July 15, 2021. Read SEC document |
| April 10, 2020 Filed Apr 14, 2020 17:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 32,246 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001493152-20-006374 · ownership.xml · derivative · entry 4 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bluestone Family Trust Disclosed balance after: 96,735 Underlying: Common Stock · 32,246 shares Expires 2029-03-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests in eight equal semi-annual installments commencing on September 27, 2019 and will become fully vested on March 27, 2023. F2 · ownership.nature: The reporting person, together with his spouse are trustees and the reporting person, his spouse and children are the beneficiaries of the Bluestone Family Trust. Read SEC document |
| April 10, 2020 Filed Apr 14, 2020 17:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | Exercise / conversionCommon Stock par value $0.0001 per share | 32,246 | $2.36 | $76,100.56 |
DisclosureSEC source: 0001493152-20-006374 · ownership.xml · nonDerivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bluestone Family Trust Disclosed balance after: 39,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 7,325 shares of common stock, par value $0.0001 per share (the "Common Stock") previously reported as being owned directly which are owned indirectly by the Bluestone Family Trust. F2 · ownership.nature: The reporting person, together with his spouse are trustees and the reporting person, his spouse and children are the beneficiaries of the Bluestone Family Trust. Read SEC document |
| February 27, 2020 Filed Apr 14, 2020 17:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GiftEmployee Stock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $12.54 | $0.00 |
DisclosureSEC source: 0001493152-20-006374 · ownership.xml · derivative · entry 6 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Bluestone Family Trust Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2029-06-24 F5 · kind: On February 27, 2020, the reporting person contributed options to purchase up to 24,000 shares of Common Stock to the Bluestone Family Trust as a gift. The option was granted on June 24, 2019, pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F6 · derivative.exercise_date: The option fully vests on May 28, 2020. F2 · ownership.nature: The reporting person, together with his spouse are trustees and the reporting person, his spouse and children are the beneficiaries of the Bluestone Family Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.